Lantern Pharma Inc. (LTRN)
LTRN Stock Price Chart
Explore Lantern Pharma Inc. interactive price chart. Choose custom timeframes to analyze LTRN price movements and trends.
LTRN Company Profile
Discover essential business fundamentals and corporate details for Lantern Pharma Inc. (LTRN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Jun 2020
Employees
24.00
Website
https://www.lanternpharma.comCEO
Panna Sharma
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
LTRN Financial Timeline
Browse a chronological timeline of Lantern Pharma Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.44.
Earnings released on 13 Aug 2025
EPS came in at -$0.40 surpassing the estimated -$0.53 by +24.53%.
Earnings released on 15 May 2025
EPS came in at -$0.42 surpassing the estimated -$0.49 by +14.29%.
Earnings released on 27 Mar 2025
EPS came in at -$0.54 falling short of the estimated -$0.51 by -5.88%.
Earnings released on 7 Nov 2024
EPS came in at -$0.42 surpassing the estimated -$0.56 by +25.00%.
Earnings released on 8 Aug 2024
EPS came in at -$0.46 surpassing the estimated -$0.55 by +16.36%.
Earnings released on 9 May 2024
EPS came in at -$0.51 falling short of the estimated -$0.43 by -18.60%.
Earnings released on 18 Mar 2024
EPS came in at -$0.39 surpassing the estimated -$0.40 by +2.50%, while revenue for the quarter reached $261.05K .
Earnings released on 8 Nov 2023
EPS came in at -$0.29 surpassing the estimated -$0.46 by +36.96%.
Earnings released on 9 Aug 2023
EPS came in at -$0.44 falling short of the estimated -$0.40 by -10.00%.
Earnings released on 9 May 2023
EPS came in at -$0.36 surpassing the estimated -$0.48 by +25.00%.
Earnings released on 20 Mar 2023
EPS came in at -$0.31 surpassing the estimated -$0.49 by +36.73%.
Earnings released on 7 Nov 2022
EPS came in at -$0.21 surpassing the estimated -$0.54 by +61.11%.
Earnings released on 8 Aug 2022
EPS came in at -$0.41 surpassing the estimated -$0.52 by +21.15%.
Earnings released on 3 May 2022
EPS came in at -$0.38 falling short of the estimated -$0.29 by -31.03%.
Earnings released on 10 Mar 2022
EPS came in at -$0.31 surpassing the estimated -$0.40 by +22.50%.
Earnings released on 1 Nov 2021
EPS came in at -$0.36 falling short of the estimated -$0.27 by -33.33%.
Earnings released on 29 Jul 2021
EPS came in at -$0.21 surpassing the estimated -$0.26 by +19.23%.
Earnings released on 3 May 2021
EPS came in at -$0.24 surpassing the estimated -$0.26 by +7.69%.
Earnings released on 10 Mar 2021
EPS came in at -$0.47 matching the estimated -$0.47.
Earnings released on 29 Oct 2020
EPS came in at -$0.27 surpassing the estimated -$0.33 by +18.18%.
LTRN Stock Performance
Access detailed LTRN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.